Drug intelligence / Profile preview

Shen Hai Long

Development stage: Unknown
Lead developer: Jiangzhong Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Shen Hai Long is a Traditional Chinese Medicine (TCM) formulation, typically administered in capsule form, developed by Zhongnan Hospital of Wuhan University. It is primarily indicated for the treatment of male asthenospermia, a condition characterized by reduced sperm motility. The formulation is designed based on TCM principles, likely focusing on tonifying the kidney and replenishing essence to improve reproductive health and sperm quality. It is currently undergoing clinical evaluation to assess its efficacy and safety in improving sperm parameters in infertile men.

Brand names: Shen Hai Long Capsule
Other names: Shen Hai Long CapsuleShenhai Long Capsule

Beyond the preview

Go deeper on Shen Hai Long.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shen Hai Long.

Explore the full profile